MetaVia Completes Last Patient Visit In Extended 24-Week Phase 1 Part 3A Study Of DA-1726

Benzinga · 18h ago

Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks